W
Winfried Häuser
Researcher at Technische Universität München
Publications - 389
Citations - 19998
Winfried Häuser is an academic researcher from Technische Universität München. The author has contributed to research in topics: Fibromyalgia & Chronic pain. The author has an hindex of 61, co-authored 361 publications receiving 15838 citations. Previous affiliations of Winfried Häuser include University of Duisburg-Essen.
Papers
More filters
Journal ArticleDOI
Systematic review and meta-analysis on non-opioid analgesics in palliative medicine.
Robert H. Schüchen,Martin Mücke,M Marinova,Dmitrij Kravchenko,Winfried Häuser,Lukas Radbruch,Rupert Conrad +6 more
TL;DR: There was substantial evidence of moderate quality for a satisfactory pain relief in cancer by non‐steroidal anti‐inflammatory drugs, flupirtine, and dipyrone compared with placebo or other analgesics and the use of acetaminophen in the palliative setting cannot be recommended.
Journal ArticleDOI
Methodological fundamentals of the development of the guideline
TL;DR: The S3-Leitlinie zum Fibromyalgiesyndrom (FMS; AWMF-Registernummer 041/004) wurde ab Marz 2011 vorgenommen.
Journal ArticleDOI
Wirksamkeit, Verträglichkeit und Sicherheit von Cannabinoiden in der Gastroenterologie
TL;DR: The medical use of Cannabis-med.org and Clinicaltrials.org for chronic bowel disease research, which aims to provide real-time information about the risks and benefits of cannabis for a wide range of medical conditions, is described.
Journal ArticleDOI
[Fibromyalgia -- a somatoform (pain) disorder?].
TL;DR: The biopsychosozial model of FM differentiating between biological as well as psychosocial predisposing, triggering, and perpetuating factors in the pathogenesis of FM is presented as an alternative model and will enable more differentiated and tailored psychotherapeutic and pharmacological treatment strategies.
Journal ArticleDOI
Fibromyalgia syndrome: novel therapeutic targets.
Jacob N. Ablin,Winfried Häuser +1 more
TL;DR: An update on novel targets in the search for effective treatment of FMS is presented and it is shown that there are no new novel targets identified that have not already been identified in the literature.